1. PRODUCT SUMMARY
GLP-1 / GIP agonist is an advanced research peptide acting as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By mimicking these two endogenous incretin hormones, GLP-1 / GIP agonist allows for the study of synergistic metabolic signaling, glycemic stabilization, and endocrine system regulation in laboratory models.
2. STORAGE & STABILITY PROTOCOL
Lyophilized Powder: Long-term storage should be maintained at -20°C (-4°F). Ensure the vial is kept away from direct light and moisture to prevent degradation.
Reconstituted Solution: Once reconstituted with bacteriostatic water or sterile saline, the solution must be stored in a refrigerator at 2–8°C (36–46°F).
Usage Window: For optimal results, it is recommended to use the reconstituted product within 7–14 days. Avoid excessive agitation or shaking of the vial.
3. RESEARCH OBJECTIVES & APPLICATIONS
This compound is intended for the following areas of laboratory investigation:
Incretin Synergy: Analyzing the combined activation of GIP and GLP-1 pathways on systemic metabolism.
Glycemic Regulation: Studying the mechanisms of glucose-dependent insulin secretion and glucagon suppression.
Energy Balance: Researching the slowing of gastric emptying and modulation of satiety centers in the brain.
Lipid Metabolism: Investigating pathways associated with adipose tissue reduction and improved peripheral insulin sensitivity.
4. REGULATORY DISCLAIMER
WARNING: This product is supplied exclusively FOR ACADEMIC AND LABORATORY RESEARCH APPLICATIONS. It is STRICTLY NOT FOR HUMAN USE, nor is it intended for any clinical, therapeutic, medical, or diagnostic procedures. This material must be handled by qualified professionals in a controlled laboratory setting only.
5. References:
- GLP-1 / GIP Agonist Once Weekly for the Treatment of Obesity
https://www.nejm.org/doi/10.1056/NEJMoa2206038 - GLP-1 / GIP Agonist Once Weekly for the Treatment of Obesity (SURMOUNT-1, PubMed)
https://pubmed.ncbi.nlm.nih.gov/35658024/ - Continued Treatment With GLP-1 / GIP Agonist for Maintenance of Weight Reduction (SURMOUNT-4)
https://jamanetwork.com/journals/jama/fullarticle/2812936 - GLP-1 / GIP Agonist for Obesity Treatment and Diabetes Prevention
https://pubmed.ncbi.nlm.nih.gov/39536238/ - Cardiovascular Outcomes with GLP-1 / GIP Agonist versus Dulaglutide (SURPASS-CVOT)
https://pubmed.ncbi.nlm.nih.gov/41406444/ - GLP-1 / GIP Agonist Once Weekly versus Placebo for Treatment of Obesity (Lancet overview)
https://www.thelancet.com/article/S0140-6736(23)01200-X/fulltext - LY3298176, a Dual GIP and GLP-1 Receptor Agonist: Preclinical Characterization
https://pubmed.ncbi.nlm.nih.gov/35658025/
Reviews
There are no reviews yet.